HUE057505T2 - UspA2-fehérjekonstrukciók és alkalmazásaik - Google Patents
UspA2-fehérjekonstrukciók és alkalmazásaikInfo
- Publication number
- HUE057505T2 HUE057505T2 HUE18211544A HUE18211544A HUE057505T2 HU E057505 T2 HUE057505 T2 HU E057505T2 HU E18211544 A HUE18211544 A HU E18211544A HU E18211544 A HUE18211544 A HU E18211544A HU E057505 T2 HUE057505 T2 HU E057505T2
- Authority
- HU
- Hungary
- Prior art keywords
- protein constructs
- uspa2 protein
- uspa2
- constructs
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1217—Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1218—Acinetobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943909P | 2014-02-24 | 2014-02-24 | |
| US201461946932P | 2014-03-03 | 2014-03-03 | |
| US201461946937P | 2014-03-03 | 2014-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057505T2 true HUE057505T2 (hu) | 2022-05-28 |
Family
ID=52629643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18211544A HUE057505T2 (hu) | 2014-02-24 | 2015-02-20 | UspA2-fehérjekonstrukciók és alkalmazásaik |
| HUE15708341A HUE042054T2 (hu) | 2014-02-24 | 2015-02-20 | UspA2-fehérjekonstrukciók és alkalmazásuk |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15708341A HUE042054T2 (hu) | 2014-02-24 | 2015-02-20 | UspA2-fehérjekonstrukciók és alkalmazásuk |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10040832B2 (enExample) |
| EP (2) | EP3110438B1 (enExample) |
| JP (1) | JP6585085B2 (enExample) |
| KR (1) | KR102515835B1 (enExample) |
| CN (2) | CN111499701A (enExample) |
| AU (1) | AU2015220369B2 (enExample) |
| BE (1) | BE1022345A9 (enExample) |
| BR (1) | BR112016019525B1 (enExample) |
| CA (1) | CA2939862C (enExample) |
| CY (2) | CY1121535T1 (enExample) |
| DK (2) | DK3110438T3 (enExample) |
| EA (1) | EA034352B1 (enExample) |
| ES (2) | ES2899300T3 (enExample) |
| HR (2) | HRP20211926T1 (enExample) |
| HU (2) | HUE057505T2 (enExample) |
| IL (1) | IL246994B (enExample) |
| LT (2) | LT3110438T (enExample) |
| ME (1) | ME03335B (enExample) |
| MX (1) | MX376079B (enExample) |
| PL (2) | PL3498292T3 (enExample) |
| PT (2) | PT3110438T (enExample) |
| RS (2) | RS58451B1 (enExample) |
| SG (1) | SG11201606272PA (enExample) |
| SI (2) | SI3110438T1 (enExample) |
| SM (2) | SMT201900166T1 (enExample) |
| TW (1) | TW201620927A (enExample) |
| UY (1) | UY36006A (enExample) |
| WO (1) | WO2015125118A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| CA3057778A1 (en) * | 2017-03-31 | 2018-10-04 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and method of treatment |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| FR3066920A1 (fr) | 2017-05-30 | 2018-12-07 | Glaxosmithkline Biologicals S.A. | Nouveaux procedes de fabrication d'un adjuvant |
| CA3072018A1 (en) | 2017-08-14 | 2019-02-21 | Glaxosmithkline Biologicals Sa | Methods of boosting immune responses |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| GB201803692D0 (en) * | 2018-03-08 | 2018-04-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| CN112912097A (zh) * | 2018-08-23 | 2021-06-04 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性蛋白和组合物 |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| BR112021024363A2 (pt) | 2019-06-05 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Purificação de saponina |
| JP2022543264A (ja) * | 2019-08-05 | 2022-10-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | プロテインｄポリペプチドを含む組成物を調製するプロセス |
| EP4010014A1 (en) | 2019-08-05 | 2022-06-15 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US20230266317A1 (en) | 2019-09-11 | 2023-08-24 | Glaxosmithkline Biologicals Sa | Antigen binding protein and assays |
| EP4294433A1 (en) | 2021-02-22 | 2023-12-27 | GlaxoSmithKline Biologicals SA | Immunogenic composition, use and methods |
| EP4558170A1 (en) | 2022-07-19 | 2025-05-28 | GlaxoSmithKline Biologicals S.A. | Continuous process for vaccine production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| ATE497004T1 (de) * | 1996-12-20 | 2011-02-15 | Univ Texas | Moraxella catarrhalis antigene uspa1 und uspa2 |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| WO2002083710A2 (en) * | 2001-04-13 | 2002-10-24 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| AU2002355197A1 (en) * | 2001-07-27 | 2003-02-17 | Chiron Srl | Meningococcus adhesins nada, app and orf 40 |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| UA95456C2 (ru) * | 2005-08-10 | 2011-08-10 | Арне Форсгрен Аб | Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента |
| US8092811B2 (en) * | 2005-08-10 | 2012-01-10 | Arne Forsgren Ab | Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| SG10201600336RA (en) * | 2006-01-17 | 2016-02-26 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| JP2014516028A (ja) * | 2011-05-11 | 2014-07-07 | リースベック ヘルスケア スウェーデン アクティエボラーグ | ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子 |
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
-
2015
- 2015-02-17 TW TW104105745A patent/TW201620927A/zh unknown
- 2015-02-20 HR HRP20211926TT patent/HRP20211926T1/hr unknown
- 2015-02-20 BR BR112016019525-6A patent/BR112016019525B1/pt not_active IP Right Cessation
- 2015-02-20 PT PT15708341T patent/PT3110438T/pt unknown
- 2015-02-20 LT LTEP15708341.1T patent/LT3110438T/lt unknown
- 2015-02-20 EA EA201691611A patent/EA034352B1/ru not_active IP Right Cessation
- 2015-02-20 WO PCT/IB2015/051308 patent/WO2015125118A1/en not_active Ceased
- 2015-02-20 SM SM20190166T patent/SMT201900166T1/it unknown
- 2015-02-20 ME MEP-2019-54A patent/ME03335B/me unknown
- 2015-02-20 JP JP2016570199A patent/JP6585085B2/ja not_active Expired - Fee Related
- 2015-02-20 LT LTEP18211544.4T patent/LT3498292T/lt unknown
- 2015-02-20 SI SI201530667T patent/SI3110438T1/sl unknown
- 2015-02-20 CN CN202010194047.1A patent/CN111499701A/zh active Pending
- 2015-02-20 CN CN201580010155.6A patent/CN106061995A/zh active Pending
- 2015-02-20 BE BE20155094A patent/BE1022345A9/fr not_active IP Right Cessation
- 2015-02-20 EP EP15708341.1A patent/EP3110438B1/en active Active
- 2015-02-20 ES ES18211544T patent/ES2899300T3/es active Active
- 2015-02-20 PL PL18211544T patent/PL3498292T3/pl unknown
- 2015-02-20 AU AU2015220369A patent/AU2015220369B2/en not_active Ceased
- 2015-02-20 HU HUE18211544A patent/HUE057505T2/hu unknown
- 2015-02-20 MX MX2016010954A patent/MX376079B/es active IP Right Grant
- 2015-02-20 CA CA2939862A patent/CA2939862C/en active Active
- 2015-02-20 RS RS20190297A patent/RS58451B1/sr unknown
- 2015-02-20 SI SI201531759T patent/SI3498292T1/sl unknown
- 2015-02-20 HR HRP20190412TT patent/HRP20190412T1/hr unknown
- 2015-02-20 PT PT182115444T patent/PT3498292T/pt unknown
- 2015-02-20 PL PL15708341T patent/PL3110438T3/pl unknown
- 2015-02-20 DK DK15708341.1T patent/DK3110438T3/en active
- 2015-02-20 SM SM20210728T patent/SMT202100728T1/it unknown
- 2015-02-20 KR KR1020167022954A patent/KR102515835B1/ko active Active
- 2015-02-20 RS RS20211446A patent/RS62592B1/sr unknown
- 2015-02-20 ES ES15708341T patent/ES2715674T3/es active Active
- 2015-02-20 SG SG11201606272PA patent/SG11201606272PA/en unknown
- 2015-02-20 DK DK18211544.4T patent/DK3498292T3/da active
- 2015-02-20 UY UY0001036006A patent/UY36006A/es not_active Application Discontinuation
- 2015-02-20 EP EP18211544.4A patent/EP3498292B1/en active Active
- 2015-02-20 HU HUE15708341A patent/HUE042054T2/hu unknown
- 2015-02-20 US US15/119,220 patent/US10040832B2/en active Active
-
2016
- 2016-07-28 IL IL246994A patent/IL246994B/en active IP Right Grant
-
2018
- 2018-06-29 US US16/023,164 patent/US10745449B2/en active Active
-
2019
- 2019-03-14 CY CY20191100307T patent/CY1121535T1/el unknown
-
2020
- 2020-06-29 US US16/914,750 patent/US10947280B2/en active Active
-
2021
- 2021-11-30 CY CY20211101038T patent/CY1124979T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400043I1 (hu) | VIII-as faktor kimérafehérjék és alkalmazásuk | |
| IL246994B (en) | Protein constructs of uspa2 and their uses | |
| IL287825A (en) | Structures of sirp-alpha variant and their uses | |
| GB201415344D0 (en) | Protein | |
| PL3702450T3 (pl) | Białko | |
| PL3099793T3 (pl) | Białko | |
| IL251289A0 (en) | New peptide derivatives and their use |